CytomX Therapeutics (CTMX) director Charles Fuchs files initial ownership report

Rhea-AI Filing Summary

CytomX Therapeutics, Inc. has an initial Form 3 statement for Charles S. Fuchs, identifying him as a director of the company. The statement reports no share purchases, sales, or derivative exercises and references Exhibit 24.1 – Power of Attorney authorizing representation in ownership reporting matters.

Key Figures

Reported share purchases: 0 Reported share sales: 0 Derivative exercises: 0 +1 more

4 metrics

Reported share purchases 0 Buy transactions count in the Form 3 transaction summary

Reported share sales 0 Sell transactions count in the Form 3 transaction summary

Derivative exercises 0 Exercise transactions count in the Form 3 transaction summary

Net buy/sell direction neutral Overall direction of reported trading activity in the summary

Key Terms

Power of Attorney, reporting person, transaction summary

3 terms

Power of Attorney regulatory

"Remarks reference Exhibit 24.1 - Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

reporting person regulatory

"The reportingPersons section lists the reporting person"

transaction summary financial

"The transactionSummary section aggregates transaction counts"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/30/2026 - 05:06 PM Accepted by SEC EDGAR 07/30/2026 - 05:05 PM Learn about SEC filing dates

FAQ

What does CytomX Therapeutics (CTMX) disclose about Charles S. Fuchs in this Form 3?

The Form 3 identifies Charles S. Fuchs as a director of CytomX Therapeutics, Inc. It is an initial ownership statement and includes a reference to Exhibit 24.1 – Power of Attorney for securities reporting matters.

Are any share transactions by Charles S. Fuchs reported for CTMX in this Form 3?

No share transactions are reported. The transaction summary shows 0 purchases, 0 sales, 0 derivative exercises, and a neutral net buy/sell direction, indicating this filing is focused on establishing his reporting status.

Does the CTMX Form 3 for Charles S. Fuchs involve any derivative securities?

No derivative activity is recorded. The summary lists 0 derivative transactions and the derivative positions section is empty, indicating no options or similar instruments are reported in this initial statement for Charles S. Fuchs.

What is the significance of Exhibit 24.1 in the CytomX (CTMX) Form 3 for Charles S. Fuchs?

The remarks reference Exhibit 24.1 – Power of Attorney, which authorizes another party to act on Charles S. Fuchs’ behalf for securities ownership reporting. This facilitates signing and submitting required ownership forms for him.

Does the CTMX Form 3 for Charles S. Fuchs indicate use of a Rule 10b5-1 trading plan?

The Rule 10b5-1 trading-plan indicator is null, meaning the record does not affirm or reference a trading plan here. Combined with no reported transactions, the filing simply establishes his status as a reporting director.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fuchs Charles S.

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/24/2026

3. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Christopher Ogden, as Attorney-in-Fact for Charles S. Fuchs	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)